Welcome to our dedicated page for Ctt Pharmaceutic news (Ticker: CTTH), a resource for investors and traders seeking the latest updates and insights on Ctt Pharmaceutic stock.
CTT Pharmaceutical Holdings, Inc. develops drug-delivery technology built around micelle-enhanced thin film and oral dissolvable strip systems. Company news centers on scientific publications, intellectual-property activity for its delivery platform, grant-related research updates, and commercialization financing tied to product development. Recurring updates also cover the company’s OTCQB trading status under the CTTH symbol and shareholder communications about its pharmaceutical development priorities, including fast-dissolving nicotine strips and applications involving diabetes-related drugs.
CTT Pharmaceuticals Holdings (OTC:CTTH) has submitted a grant application to the National Institutes of Health (NIH) to support further research and commercialization of their dissolvable nicotine strips. This submission complements an existing grant with Johns Hopkins University for clinical trials.
The initiative follows CEO Ryan Khouri's presentation at the FDA/NIH hearing for Advancing Smoking Cessation Technology. While the partnership with Johns Hopkins University remains a primary focus, CTT is pursuing additional NIH funding to advance their smoking cessation technology aimed at reducing risks of heart disease, stroke, and various cancers.
A decision on the NIH grant is expected in April 2025.
CTT Pharmaceutical Holdings (OTC:CTTH) and Johns Hopkins University have submitted a proposal for a $15 million NIH Grant to develop a smoking cessation product using CTT's patented technology. The NIH will review the proposal in April 2025.
The proposed product features fast-acting dissolvable nicotine strips that use less nicotine per dose compared to Nicorette gum and dissolve in seconds rather than 30 minutes. CTT plans to price the product competitively at or below Nicorette gum prices.
According to the World Health Organization, tobacco kills over 8 million people annually worldwide. The CDC reports smoking as the leading preventable cause of death in the United States, causing 480,000 deaths yearly. Johns Hopkins University will oversee the clinical trials if the grant is approved.
CEO Ryan Khouri has been invited to appear on Fox Business and Bloomberg regarding this grant and previously spoke at an FDA/NIH hearing about advancing smoking cessation technology.
CTT Pharmaceutical Holdings has made significant advancements in its licensing and partnership negotiations as of June 15, 2021. The company confirmed that its Canadian patent CA2624110 for orally administrable wafers now includes applications for psychedelics. With new patents accepted in Australia and Jamaica, CTT aims to leverage its technology in rapidly growing markets. The management is optimistic about potential partnerships following the dissolution of a previous agreement with Aurora. These developments position CTT to expand its reach in drug delivery systems, particularly for psychedelics and cannabinoids.